Psomagen, Inc. (KOSDAQ:950200)

Market Cap	73.48B -4.3%
Revenue (ttm)	55.98B +46.8%
Net Income	-4.20B
EPS	-208.58
Shares Out	19.24M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	47,411
Average Volume	233,322
Open	3,855.00
Previous Close	3,855.00
Day's Range	3,755.00 - 3,860.00
52-Week Range	2,910.00 - 4,665.00
Beta	-0.27
RSI	49.71
Earnings Date	Mar 20, 2026

About Psomagen

Psomagen, Inc. engages in the provision omics solutions and contract laboratory services. The company’s research services includes genomics, a study of gene sequence and expression; epigenomics, a study of epigenetic changes, such as chromatin assembly, histone modification, and DNA-protein interaction in a cell; single-cell analysis, research in suspensions, biological fluids, tissues, or cell populations; metagenomics, a study of genetic material from microorganisms in heterogeneous samples; transcriptomics, a study of RNA and its expression ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2004
• Employees: 85
• Stock Exchange: KOSDAQ
• Ticker Symbol: 950200

Financial Performance

In 2024, Psomagen's revenue was 43.66 billion, an increase of 35.29% compared to the previous year's 32.27 billion. Losses were -5.62 billion, 31.0% more than in 2023.